FDA advisory panel votes 20-2 on safety of VIVUS's (VVUS) Qnexa
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
FDA advisory panel votes 20 for, 2 against safety of VIVUS's (Nasdaq: VVUS) Qnexa.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Blue Star Gold reports phase 2 drilling results at Nutaaq target
- Ionis to present olezarsen and ION775 data at ESC Congress 2026
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
